{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T05:00:53Z","timestamp":1780117253174,"version":"3.54.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["DARU J Pharm Sci"],"DOI":"10.1007\/s40199-026-00590-5","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T03:32:59Z","timestamp":1768793579000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative efficacy of obicetrapib and anacetrapib in reducing low-density lipoprotein (LDL) levels: a network meta-analysis of clinical trials"],"prefix":"10.1007","volume":"34","author":[{"given":"Abdel Rahman","family":"Jaber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihad","family":"Abu Zayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaid","family":"Alabed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ja\u2019far","family":"Zapen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazem","family":"Ayesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"issue":"25","key":"590_CR1","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","volume":"76","author":"GA Roth","year":"2020","unstructured":"Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, Barengo NC, Beaton AZ, Benjamin EJ, Benziger CP, Bonny A, Brauer M, Brodmann M, Cahill TJ, Carapetis J, Catapano AL, Chugh SS, Cooper LT, Coresh J, Criqui M. Global burden of cardiovascular diseases and risk Factors, 1990\u20132019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76(25):2982\u20133021. https:\/\/doi.org\/10.1016\/j.jacc.2020.11.010. GBD-NHLBI-JACC Global Burden of Cardiovascular Diseases Writing Group.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"590_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12010363","volume":"12","author":"Z Du","year":"2023","unstructured":"Du Z, Qin Y. Dyslipidemia and cardiovascular disease: current knowledge, existing challenges, and new opportunities for management strategies. J Clin Med. 2023;12(1):363. https:\/\/doi.org\/10.3390\/jcm12010363.","journal-title":"J Clin Med"},{"issue":"5","key":"590_CR3","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1111\/j.1365-2125.2003.02060.x","volume":"57","author":"BM Cheung","year":"2004","unstructured":"Cheung BM, Lauder IJ, Lau CP, Kumana CR. Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. Br J Clin Pharmacol. 2004;57(5):640\u201351. https:\/\/doi.org\/10.1111\/j.1365-2125.2003.02060.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"590_CR4","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/j.jacl.2017.06.015","volume":"11","author":"ND Wong","year":"2017","unstructured":"Wong ND, Zhao Y, Quek RGW, Blumenthal RS, Budoff MJ, Cushman M, Garg P, Sandfort V, Tsai M, Lopez JAG. Residual atherosclerotic cardiovascular disease risk in statin-treated adults: the Multi-Ethnic study of atherosclerosis. J Clin Lipidol. 2017;11(5):1223\u201333. https:\/\/doi.org\/10.1016\/j.jacl.2017.06.015.","journal-title":"J Clin Lipidol"},{"issue":"2","key":"590_CR5","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1194\/jlr.M032615","volume":"54","author":"M Davidson","year":"2013","unstructured":"Davidson M, Liu SX, Barter P, Brinton EA, Cannon CP, Gotto AM Jr, et al. Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib. J Lipid Res. 2013;54(2):467\u201372. https:\/\/doi.org\/10.1194\/jlr.M032615.","journal-title":"J Lipid Res"},{"issue":"4","key":"590_CR6","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s11883-023-01087-1","volume":"25","author":"H Xue","year":"2023","unstructured":"Xue H, Zhang M, Liu J, Wang J, Ren G. Structure-based mechanism and inhibition of cholesteryl ester transfer protein. Curr Atheroscler Rep. 2023;25(4):155\u201366. https:\/\/doi.org\/10.1007\/s11883-023-01087-1.","journal-title":"Curr Atheroscler Rep"},{"issue":"5","key":"590_CR7","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1194\/jlr.R082735","volume":"59","author":"S Shrestha","year":"2018","unstructured":"Shrestha S, Wu BJ, Guiney L, Barter PJ, Rye KA. Cholesteryl ester transfer protein and its inhibitors. J Lipid Res. 2018;59(5):772\u201383. https:\/\/doi.org\/10.1194\/jlr.R082735.","journal-title":"J Lipid Res"},{"issue":"6","key":"590_CR8","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1097\/MOL.0000000000000352","volume":"27","author":"BA Di Bartolo","year":"2016","unstructured":"Di Bartolo BA, Duong M, Nicholls SJ. Clinical trials with cholesteryl ester transfer protein inhibitors. Curr Opin Lipidol. 2016;27(6):545\u20139. https:\/\/doi.org\/10.1097\/MOL.0000000000000352.","journal-title":"Curr Opin Lipidol"},{"issue":"5","key":"590_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/jcdd11050152","volume":"11","author":"WU Rehman","year":"2024","unstructured":"Rehman WU, Yarkoni M, Ilyas MA, Athar F, Javaid M, Ehsan M, et al. Cholesteryl ester transfer protein inhibitors and cardiovascular outcomes: a systematic review and meta-analysis. J Cardiovasc Dev Dis. 2024;11(5):152. https:\/\/doi.org\/10.3390\/jcdd11050152.","journal-title":"J Cardiovasc Dev Dis"},{"issue":"3","key":"590_CR10","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.amjcard.2016.10.032","volume":"119","author":"CM Ballantyne","year":"2017","unstructured":"Ballantyne CM, Shah S, Kher U, Hunter JA, Gill GG, Cressman MD, et al. Lipid-modifying efficacy and tolerability of anacetrapib added to ongoing statin therapy in patients with hypercholesterolemia or low high-density lipoprotein cholesterol. Am J Cardiol. 2017;119(3):388\u201396. https:\/\/doi.org\/10.1016\/j.amjcard.2016.10.032.","journal-title":"Am J Cardiol"},{"issue":"8","key":"590_CR11","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1038\/s41591-022-01936-7","volume":"28","author":"SJ Nicholls","year":"2022","unstructured":"Nicholls SJ, Ditmarsch M, Kastelein JJ, Rigby SP, Kling D, Curcio DL, et al. Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial. Nat Med. 2022;28(8):1672\u20138. https:\/\/doi.org\/10.1038\/s41591-022-01936-7.","journal-title":"Nat Med"},{"issue":"13","key":"590_CR12","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","volume":"377","author":"L Bowman","year":"2017","unstructured":"Bowman L, Hopewell JC, Chen F, Wallendszus K, Stevens W, Collins R, et al. Effects of anacetrapib in patients with atherosclerotic vascular disease. N Engl J Med. 2017;377(13):1217\u201327. https:\/\/doi.org\/10.1056\/NEJMoa1706444.","journal-title":"N Engl J Med"},{"issue":"4","key":"590_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003082","volume":"17","author":"A Nikolakopoulou","year":"2020","unstructured":"Nikolakopoulou A, Higgins JPT, Papakonstantinou T, Chaimani A, Del Giovane C, Egger M, et al. CINeMA: an approach for assessing confidence in the results of a network meta-analysis. PLoS Med. 2020;17(4):e1003082. https:\/\/doi.org\/10.1371\/journal.pmed.1003082.","journal-title":"PLoS Med"},{"key":"590_CR14","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.atherosclerosis.2017.03.009","volume":"261","author":"T Teramoto","year":"2017","unstructured":"Teramoto T, Daida H, Ikewaki K, Arai H, Maeda Y, Nakagomi M, et al. Lipid-modifying efficacy and tolerability of anacetrapib added to ongoing statin therapy in Japanese patients with dyslipidemia. Atherosclerosis. 2017;261:69\u201377. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2017.03.009.","journal-title":"Atherosclerosis"},{"issue":"4","key":"590_CR15","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.jacl.2023.05.098","volume":"17","author":"CM Ballantyne","year":"2023","unstructured":"Ballantyne CM, Ditmarsch M, Kastelein JJ, Nelson AJ, Kling D, Hsieh A, et al. Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: a randomized phase 2 trial. J Clin Lipidol. 2023;17(4):491\u2013503. https:\/\/doi.org\/10.1016\/j.jacl.2023.05.098.","journal-title":"J Clin Lipidol"},{"issue":"4","key":"590_CR16","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.amjcard.2017.03.255","volume":"120","author":"CM Ballantyne","year":"2017","unstructured":"Ballantyne CM, Shah S, Sapre A, Ashraf TB, Tobias SC, Sahin T, et al. A multiregional, randomized evaluation of the lipid-modifying efficacy and tolerability of anacetrapib added to ongoing statin therapy in patients with hypercholesterolemia or low high-density lipoprotein cholesterol. Am J Cardiol. 2017;120(4):569\u201376. https:\/\/doi.org\/10.1016\/j.amjcard.2017.03.255.","journal-title":"Am J Cardiol"},{"issue":"9992","key":"590_CR17","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/S0140-6736(15)60158-1","volume":"386","author":"GK Hovingh","year":"2015","unstructured":"Hovingh GK, Kastelein JJ, van Deventer SJ, Round P, Ford J, Saleheen D, et al. Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet (London, England). 2015;386(9992):452\u201360. https:\/\/doi.org\/10.1016\/S0140-6736(15)60158-1.","journal-title":"Lancet (London, England)"},{"issue":"1","key":"590_CR18","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.atherosclerosis.2013.05.012","volume":"230","author":"T Teramoto","year":"2013","unstructured":"Teramoto T, Shirakawa M, Kikuchi M, Nakagomi M, Tamura S, Surks HK, McCrary Sisk C, Numaguchi H. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with dyslipidemia. Atherosclerosis. 2013;230(1):52\u201360. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2013.05.012.","journal-title":"Atherosclerosis"},{"issue":"5","key":"590_CR19","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1111\/j.1365-2125.2009.03385.x","volume":"67","author":"R Krishna","year":"2009","unstructured":"Krishna R, Garg A, Jin B, Keshavarz SS, Bieberdorf FA, Chodakewitz J, et al. Assessment of a pharmacokinetic and pharmacodynamic interaction between Simvastatin and anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Br J Clin Pharmacol. 2009;67(5):520\u20136. https:\/\/doi.org\/10.1111\/j.1365-2125.2009.03385.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"590_CR20","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jacl.2014.09.013","volume":"9","author":"RM Krauss","year":"2015","unstructured":"Krauss RM, Pinto CA, Liu Y, Johnson-Levonas AO, Dansky HM. Changes in LDL particle concentrations after treatment with the cholesteryl ester transfer protein inhibitor anacetrapib alone or in combination with Atorvastatin. J Clin Lipidol. 2015;9(1):93\u2013102. https:\/\/doi.org\/10.1016\/j.jacl.2014.09.013.","journal-title":"J Clin Lipidol"},{"issue":"10","key":"590_CR21","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.5551\/jat.64828","volume":"31","author":"M Harada-Shiba","year":"2024","unstructured":"Harada-Shiba M, Davdison MH, Ditmarsch M, Hsieh A, Wuerdeman E, Kling D, et al. Obicetrapib as an adjunct to stable statin therapy in Japanese subjects: results from a randomized phase 2 trial. J Atheroscler Thromb. 2024;31(10):1386\u201397. https:\/\/doi.org\/10.5551\/jat.64828.","journal-title":"J Atheroscler Thromb"},{"issue":"4","key":"590_CR22","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1159\/000505365","volume":"145","author":"H Taheri","year":"2020","unstructured":"Taheri H, Filion KB, Windle SB, Reynier P, Eisenberg MJ. Cholesteryl ester transfer protein inhibitors and cardiovascular outcomes: a systematic review and meta-analysis of randomized controlled trials. Cardiology. 2020;145(4):236\u201350. https:\/\/doi.org\/10.1159\/000505365.","journal-title":"Cardiology"},{"issue":"6","key":"590_CR23","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1093\/ehjcvp\/pvac025","volume":"8","author":"K Dangas","year":"2022","unstructured":"Dangas K, Navar AM, Kastelein JJP. The effect of CETP inhibitors on new-onset diabetes: a systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother. 2022;8(6):622\u201332. https:\/\/doi.org\/10.1093\/ehjcvp\/pvac025.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"590_CR24","doi-asserted-by":"publisher","unstructured":"Masson W, Barbagelata L, Lobo M, Nogueira J, Handelsman Y. Lipid-lowering efficacy of obicetrapib: A comprehensive systematic review and meta-analysis. J Clin Lipidol. 2024;S1933\u201328742400301\u20135. https:\/\/doi.org\/10.1016\/j.jacl.2024.12.016. Advance online publication.","DOI":"10.1016\/j.jacl.2024.12.016"},{"issue":"14","key":"590_CR25","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","volume":"32","author":"Z Reiner","year":"2011","unstructured":"European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, et al. ESC\/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32(14):1769\u2013818. https:\/\/doi.org\/10.1093\/eurheartj\/ehr158.","journal-title":"Eur Heart J"},{"issue":"16","key":"590_CR26","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","volume":"372","author":"JG Robinson","year":"2015","unstructured":"Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, Shahawy E, Koren M, Lepor MJ, Lorenzato NE, Pordy C, Chaudhari R, Kastelein U. Efficacy and safety of Alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1489\u201399. https:\/\/doi.org\/10.1056\/NEJMoa1501031. J. J., & ODYSSEY LONG TERM Investigators","journal-title":"N Engl J Med"},{"issue":"18","key":"590_CR27","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1615664. FOURIER Steering Committee and Investigators.","journal-title":"N Engl J Med"},{"issue":"24","key":"590_CR28","doi-asserted-by":"publisher","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","volume":"73","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):3168\u2013209. https:\/\/doi.org\/10.1016\/j.jacc.2018.11.002.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"590_CR29","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s11883-024-01231-5","volume":"26","author":"B Chang","year":"2024","unstructured":"Chang B, Laffin LJ, Sarraju A, Nissen SE. Obicetrapib-the rebirth of CETP inhibitors? Curr Atheroscler Rep. 2024;26(10):603\u20138. https:\/\/doi.org\/10.1007\/s11883-024-01231-5.","journal-title":"Curr Atheroscler Rep"},{"issue":"2","key":"590_CR30","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1161\/01.atv.0000054658.91146.64","volume":"23","author":"PJ Barter","year":"2003","unstructured":"Barter PJ, Brewer HB Jr, Chapman MJ, Hennekens CH, Rader DJ, Tall AR. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol. 2003;23(2):160\u20137. https:\/\/doi.org\/10.1161\/01.atv.0000054658.91146.64.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"590_CR31","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s11883-023-01184-1","volume":"26","author":"JJP Kastelein","year":"2024","unstructured":"Kastelein JJP, Hsieh A, Dicklin MR, Ditmarsch M, Davidson MH. Obicetrapib: reversing the tide of CETP inhibitor disappointments. Curr Atheroscler Rep. 2024;26(2):35\u201344. https:\/\/doi.org\/10.1007\/s11883-023-01184-1.","journal-title":"Curr Atheroscler Rep"}],"container-title":["DARU Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40199-026-00590-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40199-026-00590-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40199-026-00590-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T04:05:45Z","timestamp":1780113945000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40199-026-00590-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["590"],"URL":"https:\/\/doi.org\/10.1007\/s40199-026-00590-5","relation":{},"ISSN":["2008-2231"],"issn-type":[{"value":"2008-2231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,19]]},"assertion":[{"value":"3 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. All included trials were previously approved by local ethics committees and conducted in accordance with the Declaration of Helsinki and relevant guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate declarations"}},{"value":"not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"The authors declare no competing interests.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9"}}